These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 24612500)

  • 1. Complement component C3: Serologic signature for osteogenesis imperfecta. Analysis of a comparative proteomic study.
    Kuo SJ; Wang FS; Sheen JM; Yu HR; Wu SL; Ko JY
    J Formos Med Assoc; 2015 Oct; 114(10):943-9. PubMed ID: 24612500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum Sclerostin Levels in Adults With Osteogenesis Imperfecta: Comparison With Normal Individuals and Response to Teriparatide Therapy.
    Nicol L; Wang Y; Smith R; Sloan J; Nagamani SC; Shapiro J; Lee B; Orwoll E
    J Bone Miner Res; 2018 Feb; 33(2):307-315. PubMed ID: 29044725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors and correlates of vitamin D status in children and adolescents with osteogenesis imperfecta.
    Edouard T; Glorieux FH; Rauch F
    J Clin Endocrinol Metab; 2011 Oct; 96(10):3193-8. PubMed ID: 21832107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do patients with osteogenesis imperfecta need individualized nutritional support?
    Chagas CE; Roque JP; Santarosa Emo Peters B; Lazaretti-Castro M; Martini LA
    Nutrition; 2012 Feb; 28(2):138-42. PubMed ID: 21795023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteomic analysis of plasma profiles in children with recurrent bone fractures.
    Rusińska A; Świątkowska M; Koziołkiewicz W; Skurzyński S; Golec J; Chlebna-Sokół D
    Acta Biochim Pol; 2011; 58(4):553-61. PubMed ID: 22163351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum 24,25-dihydroxyvitamin D concentrations in osteogenesis imperfecta: relationship to bone parameters.
    Edouard T; Husseini A; Glorieux FH; Rauch F
    J Clin Endocrinol Metab; 2012 Apr; 97(4):1243-9. PubMed ID: 22319032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of high-dose vitamin D supplementation on bone density in youth with osteogenesis imperfecta: A randomized controlled trial.
    Plante L; Veilleux LN; Glorieux FH; Weiler H; Rauch F
    Bone; 2016 May; 86():36-42. PubMed ID: 26924265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone geometry, density, and microarchitecture in the distal radius and tibia in adults with osteogenesis imperfecta type I assessed by high-resolution pQCT.
    Folkestad L; Hald JD; Hansen S; Gram J; Langdahl B; Abrahamsen B; Brixen K
    J Bone Miner Res; 2012 Jun; 27(6):1405-12. PubMed ID: 22407910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Teriparatide treatment in adult patients with osteogenesis imperfecta type I.
    Gatti D; Rossini M; Viapiana O; Povino MR; Liuzza S; Fracassi E; Idolazzi L; Adami S
    Calcif Tissue Int; 2013 Nov; 93(5):448-52. PubMed ID: 23907723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The 88-kDa Eales' protein in serum is a complex of haptoglobin, complement C3, and galectin-1 as identified by liquid chromatography coupled mass spectrometry.
    Ramanujam S; Muthuvel B; Aravind C B; Biswas J; Konerirajapuram NS
    Proteomics Clin Appl; 2017 Jan; 11(1-2):. PubMed ID: 27739660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
    Land C; Rauch F; Travers R; Glorieux FH
    Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum sclerostin levels are decreased in adult patients with different types of osteogenesis imperfecta.
    Kocijan R; Muschitz C; Fahrleitner-Pammer A; Amrein K; Pietschmann P; Haschka J; Dinu S; Kapiotis S; Resch H
    J Clin Endocrinol Metab; 2014 Feb; 99(2):E311-9. PubMed ID: 24203063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of bone architecture using fractal-based TX-Analyzer™ in adult patients with osteogenesis imperfecta.
    Schanda JE; Huber S; Behanova M; Haschka J; Kraus DA; Meier P; Bahrami A; Zandieh S; Muschitz C; Resch H; Mähr M; Rötzer K; Uyanik G; Zwerina J; Kocijan R
    Bone; 2021 Jun; 147():115915. PubMed ID: 33722771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of sclerostin antibody treatment in a mouse model of severe osteogenesis imperfecta.
    Roschger A; Roschger P; Keplingter P; Klaushofer K; Abdullah S; Kneissel M; Rauch F
    Bone; 2014 Sep; 66():182-8. PubMed ID: 24953712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect.
    Glorieux FH; Ward LM; Rauch F; Lalic L; Roughley PJ; Travers R
    J Bone Miner Res; 2002 Jan; 17(1):30-8. PubMed ID: 11771667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between vitamin D status and bone mineralization, mass, and metabolism in children with osteogenesis imperfecta: histomorphometric study.
    Edouard T; Glorieux FH; Rauch F
    J Bone Miner Res; 2011 Sep; 26(9):2245-51. PubMed ID: 21544864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The functional muscle-bone unit in patients with osteogenesis imperfecta type I.
    Veilleux LN; Pouliot-Laforte A; Lemay M; Cheung MS; Glorieux FH; Rauch F
    Bone; 2015 Oct; 79():52-7. PubMed ID: 26004918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of circulating pigment epithelium-derived factor is a marker of osteogenesis imperfecta type VI.
    Rauch F; Husseini A; Roughley P; Glorieux FH; Moffatt P
    J Clin Endocrinol Metab; 2012 Aug; 97(8):E1550-6. PubMed ID: 22669302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of acute-phase proteins, AHSG, C3, CLI, HP and SAA, reveals distinctive expression patterns associated with breast, colorectal and lung cancer.
    Dowling P; Clarke C; Hennessy K; Torralbo-Lopez B; Ballot J; Crown J; Kiernan I; O'Byrne KJ; Kennedy MJ; Lynch V; Clynes M
    Int J Cancer; 2012 Aug; 131(4):911-23. PubMed ID: 21953030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study.
    Rauch F; Munns CF; Land C; Cheung M; Glorieux FH
    J Bone Miner Res; 2009 Jul; 24(7):1282-9. PubMed ID: 19257821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.